查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1709462

神经保护市场，按产品类型、按疾病适应症、按作用机制、按最终用户、按国家和地区划分 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Neuroprotection Market, By Product Type, By Disease Indication, By Mechanism of Action, By End User, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 309 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年神经保护市场规模价值 340.9243 亿美元，2025 年至 2032 年的复合年增长率为 7.42%。

该市场的成长是由神经系统疾病盛行率的不断上升、医学研究的进步以及对有效治疗的需求的不断增长所推动的。此外，随着神经退化性疾病变得越来越普遍，全球人口老化进一步刺激了市场的发展。各公司正大力投资创新解决方案，以不断扩大神经保护领域的治疗选择范围。

神经保护市场-市场动态

早期神经退化性疾病诊断的生物标记发现的进展。

生物标记发现的进步在神经退化性疾病的早期诊断中发挥关键作用，极大地推动了神经保护市场的发展。生物标记有助于在神经系统疾病发作时检测出来，从而能够更早、更有效地进行干预，这对于改善患者的预后至关重要。这些发现促进了个人化治疗方法，因为生物标记可以识别特定的疾病亚型并预测进展。提高诊断精度可以确保及时治疗和更好的管理，从而降低医疗成本。

学术机构和研究组织正在引领这一进程，并透过合作推动突破。例如，美国国家老化研究所（NIA）正在积极资助阿兹海默症的生物标记研究，这已经促成了几种有前景的诊断标誌物的开发。据 NIA 称，每年拨款超过 3 亿美元用于阿兹海默症研究，其中大部分资金集中在生物标记的进展。这些发展不仅提高了诊断的准确性，而且支持了神经退化性疾病治疗中精准医疗的更广泛趋势。

神经保护市场—关键洞察

根据我们的研究分析师的分析，预计全球市场在预测期内（2025-2032 年）的年复合成长率约为 7.42%。

根据产品类型细分，预计 2024 年药物将占据最大市场份额

根据疾病适应症细分，阿兹海默症是 2024 年最主要的疾病适应症

根据作用机转细分，抗氧化剂是 2024 年最主要的作用机制

根据最终用户细分，医院是 2024 年领先的最终用户

按地区划分，北美是 2024 年的主要收入来源

神经保护市场-細項分析：

全球神经保护市场根据产品类型、疾病适应症、作用机制、最终用户和地区进行细分。

根据产品类型，市场分为两类：药物和设备。在神经保护市场中，药物是最重要的部分。由于它们在治疗阿兹海默症、帕金森氏症和多发性硬化症等神经系统疾病和病症方面发挥直接作用，因此占据了市场主导地位。包括神经保护药物在内的药物旨在减缓疾病进展、保护神经元免受损害并改善患者的生活品质。该领域受益于正在进行的研究、临床试验和监管部门的批准，推动了对新型药物治疗的需求。随着神经科学的进步带来更有效的治疗方法，神经保护药物市场预计将继续成长。

根据疾病适应症，市场分为六类：帕金森氏症、阿兹海默症、中风、多发性硬化症、肌萎缩侧索硬化症 (ALS)、创伤性脑损伤 (TBI)、其他。在神经保护市场中，阿兹海默症是最重要的疾病适应症。由于该疾病在世界范围内的流行率很高，且人口老化日益加剧，因此它占据了最大的份额。阿兹海默症会引发广泛的神经退化性病变，对旨在减缓其进展的神经保护疗法的需求庞大。药物开发的不断进步和对寻找有效治疗方法的日益关注推动了这一领域的发展。随着对创新治疗的需求不断增长，阿兹海默症仍然是研究人员和製药公司的焦点。

神经保护市场—地理洞察

受人口老化、阿兹海默症、帕金森氏症和多发性硬化症等神经退化性疾病盛行率上升以及生物技术和製药业的进步推动，北美神经保护市场正在经历显着增长。美国占最大份额，这得益于其强大的医疗保健基础设施、大量的研究资金以及对治疗方案的高需求。加拿大也透过加大对神经保护研究和开发的投资为市场做出了贡献。此外，人们越来越关注早期介入和预防治疗以及新兴药物疗法。政府措施以及学术机构和私营部门之间的合作正在促进神经保护剂的创新。然而，药物开发成本高和监管障碍等挑战依然存在。儘管如此，市场前景依然乐观，行业主要参与者正在探索新的治疗策略来满足未满足的医疗需求。

美国是北美神经保护市场的主导国家，这主要归功于其先进的医疗保健系统、高水准的研发以及政府对医疗创新的大量资助。该国拥有许多专注于神经退化性疾病的领先生物技术和製药公司，为神经保护疗法的快速发展和商业化做出了贡献。此外，美国人口数量庞大且老化，对治疗的需求不断增长，成为市场成长的主要驱动力。

神经保护市场-竞争格局：

神经保护市场的竞争格局以製药公司、生技公司和研究机构之间的激烈竞争为特征，它们都在争相开发治疗神经系统疾病的有效方法。百健（Biogen）、诺华（Novartis）和礼来（Eli Lilly）等主要公司凭藉其成熟的产品组合在阿兹海默症和帕金森氏症等神经退化性疾病领域占据主导地位。公司正专注于创新药物的发现，针对神经发炎和神经再生等新机制。市场也看到大型製药公司和小型生物技术公司之间的合作，以利用基因治疗和干细胞研究等先进技术。

神经退化性疾病的发生率不断上升以及对改进治疗方法的需求推动了市场份额的激烈竞争。监管审批流程和高昂的研发成本增加了复杂性，导致市场只剩下少数几个拥有大量资源和专业知识的主导者。新进者不断寻找利基领域和突破性疗法来使自己脱颖而出。

最新动态：

2023 年 11 月，美国食品药物管理局 (FDA) 与 BrainStorm Cell Therapeutics 会面，讨论 NurOwn，一种有可能缓解 ALS 症状的设备。会议讨论了潜在确认性 III 期试验的总体方案设计。

目录

第一章：神经保护市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 神经保护市场片段（依产品类型）
    • 神经保护市场片段（按疾病适应症）
    • 神经保护市场片段（依作用机制）
    • 神经保护市场片段（按最终用户）
    • 神经保护市场（按国家/地区）
    • 神经保护市场（按地区）
  • 竞争洞察

第三章：神经保护关键市场趋势

  • 神经保护市场驱动因素
    • 市场驱动因素的影响分析
  • 神经保护市场限制
    • 市场限制的影响分析
  • 神经保护市场机会
  • 神经保护市场未来趋势

第四章：神经保护产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：神经保护市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：神经保护市场格局

  • 2024年神经保护市场占有率分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：神经保护市场－依产品类型

  • 概述
    • 按产品类型分類的细分市场占有率分析
    • 药物
      • 抗氧化剂
      • 抗发炎药物
      • 钙通道阻断剂
      • 自由基清除剂
    • 装置

第 8 章：神经保护市场 - 按疾病适应症

  • 概述
    • 按疾病适应症分類的细分份额分析
    • 帕金森氏症
    • 阿兹海默症
    • 中风
    • 多发性硬化症
    • 肌萎缩侧索硬化症（ALS）
    • 创伤性脑损伤（TBI）
    • 其他的

第九章：神经保护市场－按作用机制

  • 概述
    • 依作用机制分析细分市场份额
    • 抗氧化剂
    • 粒线体保护
    • 发炎调节
    • 钙调节
    • 神经发生刺激
    • 基于基因治疗

第 10 章：神经保护市场 - 按最终用户

  • 概述
    • 按最终用户细分的份额分析
    • 医院
    • 诊所
    • 研究机构
    • 居家照护环境

第 11 章：神经保护市场 - 按地区划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美神经保育关键製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模和预测（按产品类型）
    • 北美市场规模及预测（依疾病类型划分）
    • 北美市场规模及预测（按作用机制）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲神经保护关键製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模和预测（按产品类型）
    • 欧洲市场规模及预测（依疾病类型划分）
    • 欧洲市场规模及预测（按作用机制）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区神经保护关键製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依产品类型）
    • 亚太地区市场规模及预测（依疾病类型划分）
    • 亚太地区市场规模及预测（依作用机制）
    • 亚太地区市场规模及预测（依最终用户）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲神经保护关键製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（依产品类型）
    • 拉丁美洲市场规模及预测（依疾病类型划分）
    • 拉丁美洲市场规模及预测（依作用机制）
    • 拉丁美洲市场规模及预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲的神经保护关键製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模及预测（依产品类型）
    • MEA 市场规模及预测（依疾病类型划分）
    • MEA 市场规模及预测（依作用机制）
    • MEA 市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 12 章：关键供应商分析-神经保护产业

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • Biogen Inc.
    • Eli Lilly and Co.
    • Novartis AG
    • Roche Holding AG
    • Merck & Co.
    • Pfizer Inc.
    • Amgen Inc.
    • AbbVie Inc.
    • Johnson & Johnson
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Lundbeck A/S
    • GlaxoSmithKline (GSK)
    • AstraZeneca plc
    • Eisai Co., Ltd.
    • Neurocrine Biosciences, Inc.
    • Axovant Gene Therapies

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4932

REPORT HIGHLIGHT

Neuroprotection Market size was valued at US$ 34,092.43 Million in 2024, expanding at a CAGR of 7.42% from 2025 to 2032.

The neuroprotection market refers to the industry focused on developing therapies and products aimed at protecting the nervous system, particularly the brain and spinal cord, from damage caused by diseases, injuries, or aging. This market addresses conditions such as Alzheimer's disease, Parkinson's disease, stroke, multiple sclerosis, and traumatic brain injuries. Neuroprotective treatments can involve drug therapies, antioxidants, neurotrophic factors, and other interventions that help prevent or reduce neuronal damage.

The growth of this market is driven by the increasing prevalence of neurological disorders, advances in medical research, and the rising demand for effective treatments. Additionally, the aging global population further fuels the market as neurodegenerative diseases become more common. Companies are heavily investing in innovative solutions, leading to an expanding range of therapeutic options in neuroprotection.

Neuroprotection Market- Market Dynamics

Advancements in biomarker discovery for early-stage neurodegenerative disease diagnosis.

Advancements in biomarker discovery play a critical role in the early diagnosis of neurodegenerative diseases, significantly driving the neuroprotection market. Biomarkers help detect neurological disorders at their onset, enabling earlier and more effective intervention, which is crucial for improving patient outcomes. These discoveries facilitate personalized treatment approaches, as biomarkers can identify specific disease subtypes and predict progression. Enhanced diagnostic precision can reduce healthcare costs by ensuring timely therapies and better management.

Academic institutions and research organizations are leading the charge, with collaborations fostering breakthroughs. For instance, the National Institute on Aging (NIA) in the U.S. is actively funding biomarker research for Alzheimer's disease, which has led to the development of several promising diagnostic markers. According to the NIA, over $300 million is allocated annually toward Alzheimer's research, much of which focuses on biomarker advancements. These developments not only enhance diagnostic accuracy but also support the broader trend of precision medicine in neurodegenerative care.

Neuroprotection Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.42% over the forecast period (2025-2032)

Based on product type segmentation, Medications was predicted to show maximum market share in the year 2024

Based on Disease Indication segmentation, Alzheimer's disease was the leading Disease Indication in 2024

Based on Mechanism of Action segmentation, Antioxidants was the leading Mechanism of Action in 2024

Based on End-User segmentation, Hospitals was the leading End-User in 2024

On the basis of region, North America was the leading revenue generator in 2024

Neuroprotection Market- Segmentation Analysis:

The Global Neuroprotection Market is segmented on the basis of Product Type, Disease Indication, Mechanism of Action, End User, and Region.

The market is divided into two categories based on product type: Medication and Devices. In the neuroprotection market, medications are the most significant segment. They dominate the market due to their direct role in treating neurological diseases and conditions like Alzheimer's, Parkinson's, and multiple sclerosis. Medications, including neuroprotective drugs, are designed to slow disease progression, protect neurons from damage, and improve patients' quality of life. This segment benefits from ongoing research, clinical trials, and regulatory approvals, driving demand for novel pharmaceutical treatments. The market for neuroprotective medications is expected to continue growing as advancements in neuroscience lead to more effective therapies.

The market is divided into six categories based on Disease Indication: Parkinson's Disease, Alzheimer's Disease, Stroke, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Others. In the neuroprotection market, Alzheimer's disease is the most significant disease indication. It holds the largest share due to the high prevalence of the disease worldwide and the increasing aging population. Alzheimer's triggers widespread neurodegeneration, creating a substantial demand for neuroprotective therapies aimed at slowing its progression. Ongoing advancements in drug development and the increasing focus on finding effective treatments have propelled this segment forward. As the need for innovative treatments grows, Alzheimer's disease remains a focal point for researchers and pharmaceutical companies.

Neuroprotection Market- Geographical Insights

The North American neuroprotection market is experiencing significant growth, driven by an aging population, increasing prevalence of neurodegenerative diseases like Alzheimer's, Parkinson's, and multiple sclerosis, and advances in biotechnology and pharmaceuticals. The U.S. holds the largest share, owing to strong healthcare infrastructure, substantial research funding, and a high demand for therapeutic solutions. Canada is also contributing to the market with growing investments in neuroprotective research and development. Furthermore, there is a rising focus on early-stage interventions and preventative treatments, as well as emerging drug therapies. Government initiatives and collaborations between academic institutions and private sectors are enhancing innovation in neuroprotective agents. However, challenges such as high drug development costs and regulatory hurdles remain. Despite this, the market outlook remains optimistic, with key players in the industry exploring novel treatment strategies to address unmet medical needs.

The United States is the dominant country in the North American neuroprotection market, largely due to its advanced healthcare system, high level of research and development, and substantial government funding for medical innovation. The country is home to many leading biotech and pharmaceutical companies focused on neurodegenerative diseases, contributing to the rapid development and commercialization of neuroprotective therapies. Additionally, the large and aging population in the U.S. presents a growing demand for treatments, making it a key driver of market growth.

Neuroprotection Market- Competitive Landscape:

The competitive landscape of the neuroprotection market is characterized by intense rivalry among pharmaceutical companies, biotech firms, and research institutions, all vying to develop effective treatments for neurological disorders. Major players such as Biogen, Novartis, and Eli Lilly dominate with established portfolios in neurodegenerative diseases like Alzheimer's and Parkinson's. Companies are focusing on innovative drug discovery, targeting new mechanisms like neuroinflammation and neuroregeneration. The market also sees collaborations between large pharmaceutical firms and smaller biotech companies to leverage advanced technologies like gene therapy and stem cell research.

The increasing prevalence of neurodegenerative diseases and the need for improved treatments drive fierce competition for market share. Regulatory approval processes and the high cost of R&D add layers of complexity, leading to a few dominant players with significant resources and expertise. New entrants are constantly looking for niche areas and breakthrough therapies to differentiate themselves.

Recent Developments:

In November 2023, the US Food and Drug Administration (FDA) met with BrainStorm Cell Therapeutics to discuss NurOwn, a device with the potential to alleviate symptoms of ALS. The meeting discussed the overall protocol design of a potential confirmatory Phase III trial.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROPROTECTION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Biogen Inc.
  • Eli Lilly and Co.
  • Novartis AG
  • Roche Holding AG
  • Merck & Co.
  • Pfizer Inc.
  • Amgen Inc.
  • AbbVie Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Lundbeck A/S
  • GlaxoSmithKline (GSK)
  • AstraZeneca plc
  • Eisai Co., Ltd.
  • Neurocrine Biosciences, Inc.
  • Axovant Gene Therapies

GLOBALNEUROPROTECTION MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Medication
  • Antioxidants
  • Anti-inflammatory drugs
  • Calcium channel blockers
  • Free radical scavengers
  • Devices

GLOBAL NEUROPROTECTION MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Parkinson's Disease
  • Alzheimer's Disease
  • Stroke
  • Multiple Sclerosis
  • Amyotrophic Lateral Sclerosis (ALS)
  • Traumatic Brain Injury (TBI)
  • Others

GLOBAL NEUROPROTECTION MARKET, BY MECHANISM OF ACTION- MARKET ANALYSIS, 2019 - 2032

  • Antioxidants
  • Mitochondrial Protection
  • Inflammation Modulation
  • Calcium Regulation
  • Neurogenesis Stimulation
  • Gene Therapy-Based

GLOBAL NEUROPROTECTION MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Research Institutes
  • Home Care Settings

GLOBAL NEUROPROTECTION MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neuroprotection Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neuroprotection Market Snippet by Product Type
    • 2.1.2. Neuroprotection Market Snippet by Disease Indication
    • 2.1.3. Neuroprotection Market Snippet by Mechanism of Action
    • 2.1.4. Neuroprotection Market Snippet by End User
    • 2.1.5. Neuroprotection Market Snippet by Country
    • 2.1.6. Neuroprotection Market Snippet by Region
  • 2.2. Competitive Insights

3. Neuroprotection Key Market Trends

  • 3.1. Neuroprotection Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neuroprotection Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neuroprotection Market Opportunities
  • 3.4. Neuroprotection Market Future Trends

4. Neuroprotection Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neuroprotection Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Neuroprotection Market Landscape

  • 6.1. Neuroprotection Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neuroprotection Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
    • 7.1.2. Medication
      • 7.1.2.1. Antioxidants
      • 7.1.2.2. Anti-inflammatory drugs
      • 7.1.2.3. Calcium channel blockers
      • 7.1.2.4. Free radical scavengers
    • 7.1.3. Devices

8. Neuroprotection Market - By Disease Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
    • 8.1.2. Parkinson's Disease
    • 8.1.3. Alzheimer's Disease
    • 8.1.4. Stroke
    • 8.1.5. Multiple Sclerosis
    • 8.1.6. Amyotrophic Lateral Sclerosis (ALS)
    • 8.1.7. Traumatic Brain Injury (TBI)
    • 8.1.8. Others

9. Neuroprotection Market - By Mechanism of Action

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Mechanism of Action, 2024 & 2032 (%)
    • 9.1.2. Antioxidants
    • 9.1.3. Mitochondrial Protection
    • 9.1.4. Inflammation Modulation
    • 9.1.5. Calcium Regulation
    • 9.1.6. Neurogenesis Stimulation
    • 9.1.7. Gene Therapy-Based

10. Neuroprotection Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Clinics
    • 10.1.4. Research Institutes
    • 10.1.5. Home Care Settings

11. Neuroprotection Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Neuroprotection Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Neuroprotection Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Neuroprotection Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Neuroprotection Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Neuroprotection Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Neuroprotection Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Biogen Inc.
    • 12.2.2. Eli Lilly and Co.
    • 12.2.3. Novartis AG
    • 12.2.4. Roche Holding AG
    • 12.2.5. Merck & Co.
    • 12.2.6. Pfizer Inc.
    • 12.2.7. Amgen Inc.
    • 12.2.8. AbbVie Inc.
    • 12.2.9. Johnson & Johnson
    • 12.2.10. Sanofi S.A.
    • 12.2.11. Teva Pharmaceutical Industries Ltd.
    • 12.2.12. Takeda Pharmaceutical Company Limited
    • 12.2.13. Lundbeck A/S
    • 12.2.14. GlaxoSmithKline (GSK)
    • 12.2.15. AstraZeneca plc
    • 12.2.16. Eisai Co., Ltd.
    • 12.2.17. Neurocrine Biosciences, Inc.
    • 12.2.18. Axovant Gene Therapies

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us